IE
BIOA

Israel Englander’s BioAge Labs BIOA Stock Holding History

Israel Englander’s Portfolio BIOA Stock Details BIOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$613K Buy
+25,000
New +$452K ﹤0.01% 4638

Other funds holding BIOA

ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Israel Englander's BIOA Position: Q2 2026 in Review

Israel Englander reduced its BioAge Labs (BIOA) stake by 48% in Q2 2026, selling an estimated $3.75M and leaving 222,621 shares worth $5.46M. The position accounts for ﹤0.01% of the portfolio, ranked #2919.

Israel Englander first reported a position in BIOA in Q3 2024 and has held it in 7 quarters since. The position peaked at $7.53M in Q1 2026. 150 funds tracked by Wall St. Rank hold BIOA as of Q2 2026.

  • Israel Englander held 222,621 shares of BioAge Labs worth $5.46M as of Q2 2026.
  • Israel Englander sold 207,842 BioAge Labs shares in Q2 2026, an estimated $3.75M.
  • BioAge Labs made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #2919 holding.
  • Israel Englander first reported a position in BioAge Labs in Q3 2024 and has held it in 7 quarters since.
  • Israel Englander's BioAge Labs position peaked at $7.53M in Q1 2026.
  • 150 funds tracked by Wall St. Rank held BioAge Labs as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.